Increased neuropeptide Y mRNA expression in striatum in Parkinson's disease

Molecular Brain Research

Volumn 110, Issue 2, 2003, Pages 169-176

  Cannizzaro, Carla ^a,b   Tel, Banu C ^a   Rose, Sarah ^a   Zeng, Bai Yun ^a   Jenner, Peter ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b 'Universita' degli Studi' of Palermo ^*  (Italy)

Author keywords

In situ hybridisation; Neuropeptide Y (NPY); Parkinson's disease; Striatum

Indexed keywords

LEVODOPA; MESSENGER RNA; NEUROPEPTIDE Y;

ADULT; AGED; ARTICLE; AUTORADIOGRAPHY; BRAIN REGION; CAUDATE NUCLEUS; CELL LABELING; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DENSITY; DOPAMINERGIC SYSTEM; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; INTERNEURON; MALE; NUCLEUS ACCUMBENS; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PUTAMEN;

AGED; CAUDATE NUCLEUS; CORPUS STRIATUM; FEMALE; GENE EXPRESSION REGULATION; HUMANS; INTERNEURONS; MALE; MIDDLE AGED; NEUROPEPTIDE Y; NUCLEUS ACCUMBENS; PARKINSON DISEASE; PUTAMEN; RNA, MESSENGER;

EID: 0037456011     PISSN: 0169328X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-328X(02)00555-7     Document Type: Article

References (31)

1. Allen J.B., Cross A.J., Crow T.J., Javoy-Agid F., Agid Y., Bloom S.R. Dissociation of neuropeptide Y and somatostatin in Parkinson's disease. Brain Res. 337:1985;197-200.
2. Beal M.F., Frank R.C., Ellison D.W., Martin J.B. The effects of neuropeptide Y on striatal catecholamines. Neurosci. Lett. 71:1986;118-123.
3. Beal M.F., Mazureck M.F., Ellison D.W., Shwartz K.J., McGarvey U., Bird E.D., Martin J.B. Somatostatin and neuropeptide Y concentration in pathologically graded cases of Huntington disease. Ann. Neurol. 23:1988;562-569.
4. Dawbarn D., Hunt S.P., Emson P.C. Neuropeptide Y: regional distribution, chromatographic characterisation and immunohistochemical demonstration in post-mortem human brain. Brain Res. 296:1984;168-173.
5. Dawbarn D., De Quidt M.E., Emson P.C. Survival of basal ganglia neuropeptide Y-somatostatin neurones in Huntington disease. Brain Res. 340:1985;251-260.
6. Eve D.J., Nisbet A.P., Kingsbury A.E., Temlett J., Marsden C.D., Foster O.J.F. Selective increase in somatostatin mRNA expression in human basal ganglia in Parkinson's disease. Mol. Brain Res. 50:1987;59-70.
7. Gaspar P., Berer B., Lesur A., Borsotti J.P., Febvret A. Somatostatin 28 and neuropeptide Y innervation in the septal area and related cortical and subcortical structures of the human brain. Distribution, relationships and evidence for differential coexistence. Neuroscience. 22:1987;49-73.
8. Gerfen C.R. The neostriatal mosaic: compartmentalization of corticostriatal input and striatonigral output systems. Nature. 311:1984;461-464.
9. Grundemar L., Hakanson R. NPY effector systems: perspectives for drug development. Trends Pharmacol. Sci. 15:1994;153-159.
10. Guttman M. Dopamine receptors in Parkinson's disease. Neurol. Clin. 10:(2):1992;377-386.
11. Heilig M., Murison R. Intracerebroventricular neuropeptide Y suppresses open field and home cage activity in the rat. Regul. Pept. 19:1987;221-231.
12. Javoy-Agid F., Ruberg M., Taquet H., Bokobza B., Agid Y., Gaspar P., Berger B., N'Guyen-Legros J., Alvarez C., Gray F., Escourolle R., Scatton B., Rouquier L. Biochemical neuropathology of Parkinson's disease. Adv. Neurol. 40:1984;189-198.
13. Kawaguchi Y., Wilson C.J., Augood S.J., Emson P.C. Striatal interneurones: chemical, physiological and morphological characterization. Trends Neurosci. 18:1995;527-535.
14. Kerkerian L., Bosler O., Pelletier G., Nieoullon A. Striatal neuropeptide Y neurones are under the influence of the nigrostriatal dopaminergic pathway: immunohistochemical evidence. Neurosci. Lett. 66:1986;106-112.
15. Kerkerian L., Salin P., Nieoullon A. Pharmacological characterization of dopaminergic influence on expression of neuropeptide Y immunoreactivity by rat striatal neurons. Neuroscience. 26:1988;809-817.
16. Kerkerian L., Salin P., Nieoullon A. Cortical regulation of striatal neuropeptide Y (NPY)-containing neurones in the rat. Putative modulatory influence on striatal dopamine-NPY relationships. Eur. J. Neurosci. 2:1990;181-189.
17. Kerkerian-Legoff L., Salin P., Vuillet J., Nieoullon A. Neuropeptide Y neurones in the striatal network. Functional adaptative responses to impairment of striatal inputs. Bernardi G., Carpenter M.B., Di Chiara G., Morelli M., Stanzione P. The Basal Ganglia III, Advance in Behavioural Biology. 1991;49-61 Plenum, New York.
18. Kingsbury A.E., Foster O.J.F., Nisbet A.P., Cairnes N., Bray L., Eve D.J., Lees A.J., Marsden C.D. Tissue pH as an indicator of mRNA preservation in human post-mortem brain. Mol. Brain Res. 28:1995;311-318.
19. 1 dopamine receptor gene. Proc. Natl. Acad. Sci. USA. 88:1991;4205-4209.
20. Lehmann J. Neuropeptide Y: an overview. Drug Dev. Res. 19:1990;329-351.
21. McDonald J.K. NPY and related substances. Crit. Rev. Neurobiol. 4:(1):1988;97-135.
22. Minth C.D., Bloom S.R., Polak J.M., Dixon J.E. Cloning, characterisation and DNA sequence of a human cDNA encoding neuropeptide tyrosine. Proc. Natl. Acad. Sci. USA. 83:1984;4577-4581.
23. Nieoullon A., Kerkerian-LeGoff L. Cellular interactions in the striatum involving neuronal systems using 'classical' neurotransmitters: possible functional implications. Mov. Disord. 7:1992;311-325.
24. Nisbet A.P., Foster O.J.E., Kingsbury A., Eve D.J., Daniel S.E., Marsden C.D., Lees A.J. Preproenkephalin and preprotachykinin messenger RNA expression in normal human and in Parkinson's disease. Neuroscience. 66:1995;361-376.
25. Nitsch C., Wolfrum G., Schaffer F., Scotti A.L., Unger J. Opposite effects of intranigral ibotenic acid and 6-hydroxydopamine on motor behaviour and on striatal neuropeptide Y neurons. Brain Res. Bull. 30:1993;21-32.
26. Salin P., Mercugliano M., Chesselet M.-F. Differential effects of chronic treatment with haloperidol and clozapine on the level of preprosomatostatin mRNA in the striatum, nucleus accumbens, and frontal cortex of the rat. Cell. Mol. Neurobiol. 10:1990;27-44.
27. Salin P., Nieoullon A., Kerkerian-LeGoff L. Reversal of the adaptative response of neuropeptide Y neurons in the rat striatum to nigrostriatal dopamine deafferentation by the N-methyl-D-aspartate antagonist dizocilpine maleate. Neuroscience. 61:1994;93-105.
28. Vuillet J., Kerkerian L., Salin P., Nieoullon A. Ultrastructural features of NPY-containing neurones in the rat striatum. Brain Res. 477:1989;241-251.
29. Vuillet J., Kerkerian L., Kachidian P., Bosler O., Nieoullon A. Ultrastructural correlates of functional relationships between nigral dopaminergic or cortical afferent fibers and neuropeptide Y-containing neurones in the rat striatum. Neurosci. Lett. 100:1989;99-104.
30. Widerlow E., Lindstrom L.H., Wahlestedt C., Ekmen R. Neuropeptide Y and peptide YY as possible markers for major depression and schizophrenia, respectively. J. Psychiatr. Res. 22:(1):1988;69-79.
31. Young W.S. III, Bonner T.I., Brann M.R. Mesencephalic dopamine neurones regulate the expression of neuropeptide mRNAs in the rat forebrain. Proc. Nat. Acad. Sci. USA. 83:1986;9827-9831.